Yigal Erlich
Managing Partner at The Yozma Group
Tel Aviv, Tel Aviv District
Yigal Erlich, Managing Partner at The Yozma Group is an active investor based in Tel Aviv, Tel Aviv District. This profile covers what Yigal Erlich backs, at which stage, and how founders can reach out in 2026.
- Investor type
- AngelVCPE
- Stages
- Pre SeedSeedSeries ASeries BLate Stage Venture
- Location
- Tel Aviv, Tel Aviv District
- Typical check
- $1M
How to reach Yigal Erlich
Angels and operators like Yigal Erlich reply to specific, personalized notes that show real traction, not mass blasts. Build a verified list, write a note that fits their thesis, and track replies, all on Round Funded.
Connect with Yigal Erlich
About this profile
This profile is part of Round Funded, an investor database and outreach platform for founders. It covers 60,000+ active VCs, angels, family offices and accelerators with verified contacts, lets you send pitches from your own Gmail, and includes a free Data Room for your raise.
Frequently Asked Questions
Who is Yigal Erlich?
Yigal Erlich is an active investor, Managing Partner at The Yozma Group. Round Funded tracks their focus and activity alongside thousands of investors.
What stage does Yigal Erlich invest at?
Yigal Erlich typically invests at Pre Seed, Seed, Series A and Series B. Lead with traction that fits the stage when you reach out.
What is Yigal Erlich's typical check size?
Yigal Erlich typically writes checks around $1M. Use it as a signal for whether your raise fits their stage.
How do I contact Yigal Erlich?
Unlock Yigal Erlich's verified email on Round Funded and send a personalized pitch. We surface only deliverable contacts so your outreach lands.
What is Round Funded?
Round Funded is an investor database and outreach platform for startup founders. It lists 60,000+ active investors with verified contacts, filtered to recent investment activity, and lets founders send personalized pitches from their own Gmail, track replies, and share a free Data Room. Round+ starts at $99 per month with a 3-day trial.